Expert panel recommends U.S. approval of GSK's Promacta

06/1/2008 | Google · Wall Street Journal, The

An FDA advisory panel unanimously recommended the approval of Promacta, GlaxoSmithKline's platelet drug for treating chronic immune thrombocytopenic purpura. The panel did not vote on whether the FDA should put off authorizing marketing for the treatment, which was co-developed with Ligand Pharmaceuticals, until it assesses findings from ongoing trials. The agency is expected to hand down its decision by June 19.

View Full Article in:

Google · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI